Back to News
Market Impact: 0.3
FDA Approves Haemonetics' PerQseal Elite For Large-Bore Arterial Procedures
Source: Nasdaq
Healthcare & BiotechProduct LaunchesCompany Fundamentals
Haemonetics received FDA approval for its PerQseal Elite vascular closure system for large-bore arterial procedures in the United States. The approval is a positive product-development milestone; the article provides no commercial outlook or financial figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
HAE0.75
More News
- Australian data center operator NextDC's shares plunge 40% after it slashes earnings forecast
- Elon Musk says Tesla and SpaceX are weighing a $3.5 trillion merger—without him in the room
- Neoclouds Lose Silver Lining as Elice, CoreWeave Dive: Evening Briefing Americas
- Anthropic May Spend $750 Billion on Computing Costs, WSJ Reports
- This Janus Henderson fund manager owns CoreWeave debt — here's why he's sticking with it
- Super Micro’s stock soars after surprise update — with Dell and HPE shares joining the rally